ASX:**ALA**

arovella THERAPEUTICS

Investor Presentation

Virtual Healthcare Conference

March 2024

NWR

Disclaimer

1. The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Arovella Therapeutics Limited (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

2. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

3. Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. The presentation includes forward-looking statements regarding future events and the future financial performance of Arovella. Forward looking words such as “expect”, “should”, “could”, “may”, “predict”, “plan”, “will”, “believe”, “forecast”, “estimate”, “target” or other similar expressions are intended to identify forward-looking statements. Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, Arovella and its officers, employees, agents or associates. In particular, factors such as outcomes of clinical trials and regulatory decisions and processes may affect the future operating and financial performance of Arovella. This may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The information also assumes the success of Arovella’s business strategies. The success of the strategies is subject to uncertainties and contingencies beyond control, and no assurance can be given that the anticipated benefits from the strategies will be realised in the periods for which forecasts have been prepared or otherwise. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements. Arovella is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

4. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

5. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

6. Any opinions expressed reflect the Company’s position at the date of this presentation and are subject to change.

7. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction in which it would be unlawful. The distribution of this presentation in jurisdictions outside Australia may be restricted by law and any such restrictions should be observed.

Arovella's strengths

Off-the-shelf iNKT Cell Platform

Developing off-the-shelf iNKT cell therapies to target blood cancers and solid tumour cancers

Lead Product Advancing to Clinic

ALA-101, a potential treatment for CD19-expressing blood cancers, is progressing to Phase 1 clinical trials, expected to commence in 2024

Addressing Key Unmet Need

Our iNKT cell platform is well positioned to solve key challenges that hamper the cell therapy sector

Strong Leadership Group

Leadership team and Board have proven experience in drug development, particularly cell therapies

Strategic Acquisitions

Focused on acquiring innovative technologies that strengthen the iNKT cell therapy platform and align with core focus areas

Unique Value Proposition

Arovella is among few companies globally developing an iNKT cell therapy platform

Arovella's iNKT cell strategy

Incorporating world class IP to target a range of tumour types



Exclusive worldwide rights to granted patents

Further patent claims and applications actively being pursued



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
06 September 2019 (06.09.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/166817 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01)

(21) International Application Number:
PCT/GB20 19/050570

(22) International Filing Date:
28 February 2019 (28.02.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1803376.1 01 March 2018 (01.03.2018) GB

(71) Applicant: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE [GB/GB]; South Kensington Campus, Faculty Building, Exhibition Road, London SW7 2AZ (GB).

(72) Inventors: KARADIMITRIS, Anastasios; C/O Imperial College London, Du Cane Road, London Greater London W12 0NN (GB). ROTOLO, Antonia; C/O Imperial College London, Du Cane Road, London Greater London W12 0NN (GB).

(74) Agent: HGF LIMITED; Document Handling - HGF (Manchester), 1 City Walk, LEEDS Yorkshire LS1 1 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA

- **Transduction and Expansion of Cells**
- Patent life until 2038
- Method of manufacture, cell population claims
- Applicant: Imperial College of Science Technology and Medicine
- Granted in Europe, pending in Canada, Hong Kong, China and Australia
- Worldwide exclusive rights for human disease



(19) United States

(12) Patent Application Publication
Zhu et al.

(10) Pub. No.: US 2020/0207857 A1

(43) Pub. Date: Jul. 2, 2020

(54) BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITIONS AND METHODS THEREOF, FOR THE TREATMENT OF CANCER AND OTHER DISEASES

(71) Applicant: Sparx Therapeutics Inc., Mt. Prospect, IL (US)

(72) Inventors: Guidong Zhu, Gurnee, IL (US); Jingdong Ye, Vernon Hills, IL (US); Jingdong Qin, Woodridge, IL (US); Jichun Ma, Germantown, MD (US)

(73) Assignee: Sparx Therapeutics Inc., Mt. Prospect, IL (US)

(21) Appl. No.: 16/727,554

(22) Filed: Dec. 26, 2019

Related U.S. Application Data

(52) U.S. Cl.
CPC *C07K 16/2827* (2013.01); *C12N 15/85* (2013.01); *C07K 2317/515* (2013.01); *C07K 2317/54* (2013.01); *C07K 2317/51* (2013.01); *C07K 2317/622* (2013.01); *C07K 2317/734* (2013.01); *C07K 2317/732* (2013.01); *C12N 2015/8518* (2013.01); *C07K 2317/55* (2013.01)

(57) ABSTRACT

Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragments thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudin, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, breast cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent

- **Binding Molecules Specific for Claudin 18.2**
- Patent life until 2038
- Composition of matter claims for a unique CLDN18.2 monoclonal antibody sequence
- Applicant: Sparx Therapeutics Inc.
- Granted in USA, pending in Europe, China, Japan and South Korea
- Worldwide exclusive rights for use in Cell Therapies

Financial overview

Financial Snapshot

ASX CODE	ALA
Market capitalisation[1]	$143.4 million
Shares on issue	925.1 million
52-week low / high[1]	$0.033 / $0.185
Cash Balance (Dec 31 2023)	$4.76 million

Major Shareholders

Shareholder	Ownership (%) [1]
THE TRUST COMPANY (AUSTRALIA) LIMITED	56,186,926 (6.12%)
RICHARD JOHN MANN	50,905,657 (5.54%)
UBS NOMINEES PTY LTD	20,620,196 (2.25%)
BLACKBURNE CAPITAL PTY LTD	18,407,456 (2.00%)
DYLIDE PTY LTD	15,666,666 (1.71%)

1. *As of 8 March 2024*

ALA Price and Volume - 12 Months[1]



Recent cell therapy transactions[1]

Date	Type of deal	Acquirer/Licensee	Target/Licensor	Cell Type	Stage	Upfront (US$M)	Milestones (US$M)	Total deal value (US$M)
Dec-23	Acquisition	AstraZeneca	GRACELL	T Cell	Phase 1b	$1,000	$200	$1,200
Nov-23	Collaboration and investment[2]	AstraZeneca	cellectis	Not specified	Platform	$25	$70-220 per product	
Aug-23	Licence[3]	IMUGENE Developing Cancer Immunotherapies	PRECISION BIOSCIENCES	T Cell	Phase 1b	$21	$206	$227
Aug-23	Strategic investment (ROFR) [4]	astellas	POSEIDA THERAPEUTICS	T Cell	Phase 1	$25	$0	$25
May-23	Licence	janssen	CBMG Cellular Biomedicine Group	T Cell	Phase 1b	$245	*undisclosed*	
Jan-23	Acquisition	AstraZeneca	neogene THERAPEUTICS	T Cell	Phase 1	$200	$120	$320
Oct-22	Development collaboration[5]	GILEAD	ARCELLX	T Cell	Phase 2	$225	*undisclosed*	
Sep-22	Research collaboration	Genentech A Member of the Roche Group	ArsenalBio	T Cell	Preclinical	$70	*undisclosed*	
Aug-22	Licence & strategic collaboration	Roche	POSEIDA THERAPEUTICS	T Cell	Phase 1	$110	$110	$220
Sep-21	Development collaboration	Genentech A Member of the Roche Group	Adaptimmune	T Cell	Preclinical	$150	$150	$300
Aug-21	Research collaboration	GILEAD	APPIA BIO	iNKT Cell	Preclinical	*undisclosed*	*undisclosed*	$875
May-21	Acquisition	Athenex	kuur THERAPEUTICS	iNKT Cell	Phase 1	$70	$115	$185
Jun-21	Acquisition	eterna	Novellus THERAPEUTICS	Multiple	Preclinical	$125	$0	$125

1. *See the last slide for deal references*
2. *Cellectis will receive a US$220m equity investment from Astra Zeneca plus tiered royalties. Milestones are payable for 10 products*
3. *Precision is eligible for double digit royalties on net sales and $145 million in milestone payments and tiered royalties for additional programs*
4. *Poseida also received a US$25m equity investment from Astellas*
5. *Arcellx also received a US$100m equity investment from Gilead*

How original CAR-T cell therapies work

CAR-T cell therapy is personalised medicine



T cells = immune cell

T cells are a common type of immune cell that fight infections and can help fight cancer.

T cells from patient 'reprogrammed'

To generate autologous CAR-T cells, T cells are taken from a patient with blood cancer and 'reprogrammed' to produce a Chimeric Antigen Receptor (CAR). The CAR can recognise cancer cells through a target antigen.

CAR-T cells find & kill tumour cells

CAR-T cells are administered to the patient to find and kill the tumour cells. Once the CAR binds to a tumour cell, the CAR-T cell is activated to kill the tumour cell.

https://www.ohsu.edu/sites/default/files/2021-04/CAR%20TcellTherapy7-700px.jpg

Cell Therapy has revolutionised blood cancer treatment

CAR-T cells have demonstrated their curative potential in blood cancers

The Cell Therapy market is expected to reach

$61.2 billion

by 2030[1]

Cure

CAR-T cells have demonstrated ability to **cure haematological cancers**

Strong Sales

40-60%

Patients relapse post-CAR-T therapy[2]

Product	Approval Year	2023 Revenu
YESCARTA (axicabtagene ciloleucel)	2017	US$1498m
KYMRIAH (tisagenlecleucel)	2017	US$509m
Abecma (idecabtagene vicleucel)	2021	US$472m

1. https://www.businesswire.com/news/home/20230529005130/en/Global-Cell-Therapy-Market-Report-2023-Advancements-in-Biotechnology-Drives-Growth---ResearchAndMarkets.com
2. Zinzi et al., 2023 Pharmacological Research - 10.1016/j.phrs.2023.106742
3. https://www.gilead.com/news-and-press/press-room/press-releases/2024/2/gilead-sciences-announces-fourth-quarter-and-full-year-2023-financial-results#:~:text=Yescarta%C2%AE%20(axicabtagene%20ciloleucel)%20sales,%E2%80%9D)%20outside%20the%20United%20States.
4. https://www.novartis.com/sites/novartis_com/files/2024-01-interim-financial-report-en.pdf
5. https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2023/default.aspx

Emily Whitehead - **Celebrating 10 years of CAR-T cell therapy**

https://emilywhiteheadfoundation.org/10-years-of-car-t/

Autologous CAR-T pose challenges

The current manufacturing costs and time are limiting



Each manufacturing batch is **patient-specific**

Patient must wait **3-4 weeks** for therapy

- Manufacturing & supply chain **costs are high**
- T cells **can be compromised** due to disease
- **Limited centres** can collect and manufacture
- **Time is an issue** for patients with aggressive disease
- Manufacturing run **failures can occur**

Allogeneic

A single healthy donor batch = treatment for multiple patients



1 week

Patients ready to dose within 1 week

Introducing invariant Natural Killer T (iNKT) cells

Bridging the innate and adaptive immune system



iNKT cells represent a next-generation cell therapy

Properties make them ideal for use in cell therapy



Strong safety profile

- Don't cause graft versus host disease (GvHD)

Front line of the human immune system

- Bridge innate & adaptive immune responses
- Contain both T cell & NK cell killing mechanisms
- Naturally target & kill cancers that express CD1d

Multiple anti-cancer properties

- Shape the tumour microenvironment by blocking/killing pro tumour cells (TAMs/MDSCs)
- Infiltrate tumours & secrete signaling molecules to activate other immune cells to kill tumour cells

A differentiated position

T cell and NK cell sectors are competitive



Companies with T cell, NK cell, or iNKT cell therapy programs.
Source: Company analysis based on public information

CAR-iNKT cell therapy production advantages

Off-the-shelf manufacturing advantages

MANUFACTURING

Collect Healthy Donor Blood

Isolate iNKT cells





Engineer iNKT cells to produce a CAR

Expand to grow billions of CAR-iNKT cells



Vial and freeze CAR-iNKT cells

TREATMENT

Thaw CAR-iNKT cells

Dose eligible patients



Healthier starting material
Potentially better efficacy

Scalable manufacturing with reduced costs
Reach more patients

Faster access to treatment
Improved outcomes for aggressive cancers

Removes risk of manufacturing run failure
Stored frozen, ready for use

ALA-101 (CAR19-iNKT cells)

A next generation **off-the-shelf** cell therapy for CD19 expressing cancers

ALA-101: enhanced tumour killing *in vivo*

ALA-101 rapidly eradicates tumour cells in mice

- Tumour cells expressing **CD19** and **CD1d** were intravenously delivered into mice
- Mice were treated with:
  - PBS (saline)
  - Unmodified T cells (T)
  - Unmodified iNKT cells (iNKT)
  - CAR19-T cells
  - ALA-101 (CAR19-iNKT cells)
- After three days, ALA-101 resulted in significant regression of tumour cells
- In all other treatments, there was strong tumour cell persistence
- ALA-101 displays swift action



Rotolo *et al.*, Cancer Cell (20

ALA-101: next generation cell therapy

ALA-101 significantly increased survival in mice versus treatment with CAR19-T cells

- Tumour cells expressing **CD19** and **CD1d** were intravenously delivered into mice
- Mice were treated with:
  - PBS (saline)
  - Unmodified T cells (T)
  - Unmodified iNKT cells (iNKT)
  - CAR19-T cells
  - ALA-101 (CAR19-iNKT cells)
- After 90 days, only mice treated with CAR19-T cells or ALA-101 remained alive
- 1.5x more mice treated with ALA-101 remained alive after 90 days relative to CAR19-T cells
- ALA-101 has the potential to be an effective, off-the-shelf cell therapy for the treatment of CD19-expressing cancers



Rotolo *et al.*, Cancer Cell (20

ALA-101: spontaneous secondary remission

ALA-101 activity may persist to eradicate tumour cells following relapse

- Four mice treated with ALA-101 had the cancer return to the brain
- In all four mice, the cancer was eliminated a second time with no additional dosing
- This provides evidence that CAR19-iNKT cells can survive and continue to protect against cancer cells in vivo
- Potential to use ALA-101 to treat central nervous system lymphoma or brain metastases



Rotolo *et al.*, Cancer Cell (20

Progress towards first-in-human clinical trials

ALA-101 data confirms activity and off-the-shelf capability

Potent antitumour activity

Demonstrated efficacy of ALA-101 against CD19+ ymphomas and leukemias. Proof-of-concept data with clinical-designed lentiviral vector in animal models sing thawed, “off-the-shelf” ALA-101.

Expected to be safe

iNKT cells have been shown in clinical trials not to cause graft versus host disease (GvHD) and the CD19 targeting CAR (FMC63) is a validated targeting agent in approved cell therapies.

Multiple dose manufacturing

ALA has demonstrated that its manufacturing process can produce a high number of CAR+ cells with potent cell killing properties and has completed production of GMP-grade lentivirus for CD19 CAR expression.

Phase 1 clinical trial anticipated CY 2024





iNKT cells to target solid tumours

Arovella is implementing its strategy to target and kill solid tumours – 90% of newly diagnosed cancer cases[1]

1. *https://www.cancer.gov/types/common-cancers*

Solid tumours pose challenges to cell therapies

Solid tumours are more
difficult to treat with cell therapies

- Access to tumour
- Antigen specificity and uniformity
- Tumour microenvironment (TME) contains cells that support cancer cell growth



Solid tumour



Blood cancer

iNKT cells:

- Home to tissues and infiltrate tumours
- Modify the TME to block or kill cells that promote tumour growth and recruit helpful immune cells

TAM = Tumour Associated Macrophage; MDSC = Myeloid Derived Suppressor Cell; CAR = Chimeric Antigen Receptor

Arovella's strategies to combat solid tumours

Arovella is using three approaches to expand the iNKT cell platform into solid tumours

License novel cancer targets

Identify and license new targets that are expressed in multiple cancers to incorporate into Arovella's iNKT cell therapy platform

Armour iNKT cells

Enhance the performance of iNKT cells by equipping iNKT cells with novel armouring technologies

Create unique partnerships

Create partnerships to use novel combination therapies with synergistic effects

Add additional CARs for novel targets

STRATEGY 1

Arovella's manufacturing process can be leveraged for multiple cancer types

MANUFACTURING

Collect Healthy Donor Blood

Isolate iNKT cells





Engineer iNKT cells to produce a CAR

Expand to grow billions of CAR-iNKT cells



Vial and freeze CAR-iNKT cells

CARs targeting novel antigens specific for solid tumours

can be incorporated into iNKT cells

using the same manufacturing process



New lentiviral vector generated for each new CAR

Introducing Claudin 18.2 (CLDN18.2)

A promising solid tumour target

CLDN18.2 overexpression has been

identified in several types of cancers

- gastric cancer **(GC)**
- gastroesophageal junction cancer **(GEJC)**
- pancreatic cancer **(PC)**
- esophageal cancer **(EC)**
- ovarian adenocarcinoma **(OAC)**
- lung cancers **(LC)**



Validated target

with first monoclonal antibody expected to be **approved in 2024**

Gastric cancer

market alone expected to reach **$10.7 billion** by 2031[1]

1. https://www.alliedmarketresearch.com/gastric-cancer-market-A74458#:~:text=The%20global%20gastric%20cancer%20market,cells%20lining%20of%20the%20stomach

“Armouring” CAR-iNKT cells

STRATEGY 2

IL-12-TM (cytokine technology) enhances CAR-iNKT cell activity in solid tumours



IL-12-TM

IL-12-TM is a modified version of IL-12

with a membrane anchor that links it to the surface of CAR-iNKT cells. By linking it to the surface of iNKT cells, it can enhance CAR-iNKT cells without being released into the blood stream making it safer.

The IL-12-TM is incorporated into the lentiviral vector system and

does not require changes to the manufacturing process

iNKT cells + IL-12-TM

Expand more and survive for longer
than CAR-iNKT cells lacking the cytokine

10x more circulating CAR-iNKT cells
4 weeks after treatment in a mouse model

Superior anti-tumour activity
compared to CAR-iNKT cells lacking the cytokine

The technology has been published in the prestigious, peer reviewed journal, **Nature Communications**

nature › nature communications › articles › article

Article | Open access | Published: 02 January 2024

IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity

Arovella's expanding pipeline

PRODUCT	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1
ALA-101 (CAR19-iNKT) 	CD19 Expressing cancers	CD19 Expressing Lymphoma		
ALA-105 (CLDN18.2-iNKT) 	CLDN18.2 positive solid tumours	Gastric & Pancreatic Cancers		
IL-12-TM 	Solid Tumours	Solid Tumours		

Upcoming milestones for 2024

anuary
2024

July
2024

December
2024

	January 2024	July 2024	December 2024
ALA-101 (CD19)	▪ Complete cGMP manufacture for Phase 1 clinical trials ▪ Complete preparatory activities for Phase 1 study, including preparation of regulatory dossier, engagement with clinical sites and KOLs	▪ Commence Phase 1 for ALA-101 targeting CD19+ lymphoma and leukemia	
ALA-105 (CLDN18.2)	▪ Initiate proof-of-concept testing for CLDN18.2-iNKT cells to expand iNKT platform for treatment of solid tumours ▪ Optimise the CAR construct for robust efficacy	▪ Generate animal data for CLDN18.2 targeting CAR-iNKT cells against gastric cancer and/or pancreatic cancer ▪ Commence activities to manufacture ALA-105 for clinic (e.g. lentiviral vector)	
IL-12-TM Integration	▪ Integrate IL-12-TM into solid tumour programs and test its efficacy in anti-tumour models ▪ Enter into a Sponsored Research Agreement (SRA) with Professor Gianpietro Dotti's research group		

Expect to advance ALA-101 to Phase 1 first-in-human clinical trial during 2024

Dose escalation Phase 1 study in patients with CD19+ blood cancers

cGMP – Current Good Manufacturing Practice; KOLs – key opinion leaders

Summary

Novel allogeneic CAR-iNKT cell platform

NKT cells serve as an excellent platform to develop allogeneic, or “off-the-shelf”, cell therapies to treat cancer

Improved manufacturing logistics

Allogeneic CAR-iNKT cells will significantly improve ogistics and increase patient access

AR-iNKT cells have multiple anticancer properties

AR-iNKT cells have multiple anti-cancer properties that may support enhanced efficacy over other immune cell types



Arovella’s CAR-iNKT Cell Platform

Lead product progressing to clinical trials

ALA-101, a potential treatment for CD19-expressing blood cancers, is being progressed to Phase 1 clinical trials, expected to commence in 2024

Arovella has an expanding pipeline

Arovella continues to expand the iNKT cell platform to potentially treat solid tumours

Arovella is poised for growth

Arovella is developing a cutting-edge CAR-iNKT cell therapy platform, with an expanding pipeline and a strong leadership team

ASX:ALA

arovella
THERAPEUTICS

Thank You

Dr. Michael Baker

CEO & Managing Director

Email: investor@arovella.com
Mobile: +61 403 468 187

Cell therapy deal references

1. *https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html*
2. *https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html*
3. *https://www.businesswire.com/news/home/20230815091930/en/Precision-BioSciences-Completes-Strategic-Transaction-with-Imugene-for-Azer-Cel-in-Cancer*
4. *https://www.astellas.com/en/news/28271*
5. *https://www.jnj.com/janssen-enters-worldwide-collaboration-and-license-agreement-with-cellular-biomedicine-group-to-develop-next-generation-car-t-therapies*
6. *https://www.astrazeneca.com/media-centre/press-releases/2023/acquisition-of-neogene-therapeutics-completed.html*
7. *https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/kite-and-arcellx-announce-strategic-collaboration-to-co-develop-and-co-commercialize-late-stage-clinical-cart-ddbcma-in-multiple-myeloma*
8. *https://www.fiercebiotech.com/biotech/genentech-pays-70m-access-arsenals-armoury-t-cell-tools-quest-solid-tumor-car-t*
9. *https://www.prnewswire.com/news-releases/poseida-therapeutics-announces-strategic-global-collaboration-with-roche-focused-on-allogeneic-car-t-cell-therapies-for-hematologic-malignancies-301598555.html*
10. *https://www.adaptimmune.com/investors-and-media/news-center/press-releases/detail/197/adaptimmune-enters-into-a-strategic-collaboration-with*
11. *https://www.gilead.com/news-and-press/press-room/press-releases/2021/8/kite-and-appia-bio-announce-collaboration-to-research-and-develop-allogeneic-cell-therapies-for-cancer*
12. *https://www.nasdaq.com/articles/athenex-snaps-up-kuur-therapeutics-for-$185m-street-sees-133.7-upside-2021-05-05*
13. *https://eternatx.com/news/brooklyn-immunotherapeutics-completes-acquisition-of-eterna-therapeutics/*